{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:49:44Z","timestamp":1794091784356,"version":"4.8.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"67","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Institute of Health Research Foundation","award":["FDN-143283"],"award-info":[{"award-number":["FDN-143283"]}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP48979"],"award-info":[{"award-number":["OPP48979"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Single-Dose HPV vaccine consortium - PATH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A concern in high-income countries is that switching to 1-dose human papillomavirus (HPV) vaccination could cause a rebound in HPV infection and cervical cancer if 1-dose efficacy or duration were inferior to 2 doses. Using mathematical modeling and up-to-date trial-based data, we projected the population-level effectiveness of switching from 2-dose to 1-dose vaccination under different vaccine efficacy and duration assumptions in high-income countries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used HPV-ADVISE (Agent-based Dynamic model for VaccInation and Screening Evaluation), a transmission-dynamic model of HPV infection and cervical cancer, varying key model assumptions to identify those with the greatest impact on projections of HPV-16 and cervical cancer incidence over time: 1) 1-dose vaccine efficacy and vaccine duration, 2) mechanisms of vaccine efficacy and duration over time, 3) midadult (&amp;gt;30 years of age) sexual behavior, 4) progression to cervical cancer among midadults, and 5) vaccination coverage and programs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In high-income countries, 1-dose vaccination would cause no appreciable rebound in HPV-16 infection, except for a limited rebound under the most pessimistic assumptions of vaccine duration (average, 25 years), because 1) the switch would occur when HPV prevalence is low because of high 2-dose vaccination coverage and 2) individuals would be protected during their peak ages of sexual activity (&amp;lt;35 to 40 years of age). Our model projects a more limited rebound in cervical cancer because of a shift to older age at infection, resulting in fewer life-years left to potentially develop cancer. Projections were robust when varying key model assumptions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>High protection during peak ages of sexual activity in high-income countries would likely mitigate any potential rebounds in HPV infection and cervical cancer under the most pessimistic assumptions of 1-dose efficacy and duration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncimonographs\/lgae038","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T08:03:05Z","timestamp":1731398585000},"page":"387-399","source":"Crossref","is-referenced-by-count":9,"title":["Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling"],"prefix":"10.1093","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3912-6447","authenticated-orcid":false,"given":"Marc","family":"Brisson","sequence":"first","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Sociale et Pr\u00e9ventive, Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]},{"name":"Centre de Recherche du CHU de Qu\u00e9bec - Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7938-1400","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Laprise","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec - Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Drolet","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec - Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9l\u00e9onore","family":"Chamberland","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec - Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lodie","family":"B\u00e9nard","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Sociale et Pr\u00e9ventive, Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]},{"name":"Centre de Recherche du CHU de Qu\u00e9bec - Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-5849","authenticated-orcid":false,"given":"Emily A","family":"Burger","sequence":"additional","affiliation":[{"name":"Center for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["USA"]},{"name":"Department of Health Management and Health Economics, University of Oslo , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-8255","authenticated-orcid":false,"given":"Mark","family":"Jit","sequence":"additional","affiliation":[{"name":"Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical Medicine , London,","place":["UK"]},{"name":"School of Public Health, University of Hong Kong , Hong Kong SAR,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri E","family":"Markowitz","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, GA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-1658","authenticated-orcid":false,"given":"Chantal","family":"Sauvageau","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Sociale et Pr\u00e9ventive, Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]},{"name":"Centre de Recherche du CHU de Qu\u00e9bec - Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]},{"name":"Institut National de Sant\u00e9 Publique du Qu\u00e9bec et Direction R\u00e9gionale de Sant\u00e9 Publique de la Capitale-Nationale , Qu\u00e9bec, Qu\u00e9bec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Sy","sequence":"additional","affiliation":[{"name":"Center for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"issue":"5","key":"2024111222512048900_lgae038-B1","doi-asserted-by":"crossref","first-page":"EVIDoa2100056","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose human papillomavirus vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evid"},{"issue":"11","key":"2024111222512048900_lgae038-B2","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"Basu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024111222512048900_lgae038-B3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"97","key":"2024111222512048900_lgae038-B4","first-page":"645","article-title":"Human papillomavirus vaccines: WHO position paper (2022 update)","volume":"50","author":"World Health Organization (WHO)","year":"2022","journal-title":"Weekly Epidemiol Rec"},{"issue":"10","key":"2024111222512048900_lgae038-B5","doi-asserted-by":"crossref","first-page":"e788","DOI":"10.1016\/S2468-2667(23)00180-9","article-title":"Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis","volume":"8","author":"B\u00e9nard","year":"2023","journal-title":"Lancet Public Health"},{"issue":"1","key":"2024111222512048900_lgae038-B6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12916-023-02988-3","article-title":"Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis","volume":"21","author":"Prem","year":"2023","journal-title":"BMC Med"},{"key":"2024111222512048900_lgae038-B7","volume-title":"35nd International Papillomavirus Conference (IPVC).","author":"Romero","year":"2023"},{"key":"2024111222512048900_lgae038-B8","volume-title":"J Natl Cancer Inst Monogr","author":"Porras","year":"2024"},{"key":"2024111222512048900_lgae038-B9","volume-title":"35nd International Papillomavirus Conference (IPVC).","author":"Basu","year":"2023"},{"key":"2024111222512048900_lgae038-B10","author":"Malvi","year":"2024"},{"issue":"12","key":"2024111222512048900_lgae038-B11","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","article-title":"Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results","volume":"29","author":"Barnabas","year":"2023","journal-title":"Nat Med"},{"key":"2024111222512048900_lgae038-B12","author":"World Health Organization (WHO)","year":"2024"},{"key":"2024111222512048900_lgae038-B13","author":"World Health Organization (WHO)"},{"key":"2024111222512048900_lgae038-B14","doi-asserted-by":"crossref","first-page":"106399","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019","volume":"144","author":"Bruni","year":"2021","journal-title":"Preventive Medicine"},{"issue":"10197","key":"2024111222512048900_lgae038-B15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"2024111222512048900_lgae038-B16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.15585\/mmwr.mm7012a2","article-title":"Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine\u2014United States, 2003-2018","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"45","key":"2024111222512048900_lgae038-B17","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1016\/j.vaccine.2023.10.002","article-title":"The impact of over ten years of HPV vaccination in England: surveillance of type-specific HPV in young sexually active females","volume":"41","author":"Checchi","year":"2023","journal-title":"Vaccine"},{"issue":"2","key":"2024111222512048900_lgae038-B18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ijc.34231","article-title":"HPV type-specific trends in cervical precancers in the United States, 2008 to 2016","volume":"152","author":"Gargano","year":"2023","journal-title":"Int J Cancer"},{"issue":"14","key":"2024111222512048900_lgae038-B19","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.vaccine.2022.02.067","article-title":"Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: an analysis in the United Kingdom","volume":"40","author":"Daniels","year":"2022","journal-title":"Vaccine"},{"key":"2024111222512048900_lgae038-B20","doi-asserted-by":"crossref","first-page":"g7584","DOI":"10.1136\/bmj.g7584","article-title":"Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model","volume":"350","author":"Jit","year":"2015","journal-title":"BMJ"},{"issue":"26","key":"2024111222512048900_lgae038-B21","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1016\/j.vaccine.2014.03.098","article-title":"Two-dose strategies for human papillomavirus vaccination: How well do they need to protect?","volume":"32","author":"Jit","year":"2014","journal-title":"Vaccine"},{"issue":"44","key":"2024111222512048900_lgae038-B22","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1016\/j.vaccine.2014.07.099","article-title":"Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study","volume":"32","author":"Laprise","year":"2014","journal-title":"Vaccine"},{"issue":"22","key":"2024111222512048900_lgae038-B23","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model\u2013based analysis","volume":"104","author":"Van de Velde","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2024111222512048900_lgae038-B24","doi-asserted-by":"crossref","first-page":"djv282","DOI":"10.1093\/jnci\/djv282","article-title":"Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States","volume":"108","author":"Brisson","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"37","key":"2024111222512048900_lgae038-B25","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2013.06.064","article-title":"Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study","volume":"31","author":"Brisson","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"2024111222512048900_lgae038-B26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7326\/M19-1182","article-title":"Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States","volume":"172","author":"Laprise","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024111222512048900_lgae038-B27","author":"Comit\u00e9 sur l\u2019immunisation du Qu\u00e9bec (CIQ)"},{"key":"2024111222512048900_lgae038-B28","author":"Comit\u00e9 sur l\u2019immunisation du Qu\u00e9bec (CIQ)"},{"issue":"49","key":"2024111222512048900_lgae038-B29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination\u2013updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"2024111222512048900_lgae038-B30","author":"Joint Committee on Vaccination and Immunisation (JCVI)"},{"key":"2024111222512048900_lgae038-B31","author":"Joint Committee on Vaccination and Immunisation (JCVI)"},{"key":"2024111222512048900_lgae038-B32","author":"World Health Organization (WHO)"},{"issue":"47","key":"2024111222512048900_lgae038-B33","first-page":"541","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, October 2019: conclusions and recommendations","volume":"94","author":"World Health Organization (WHO)","year":"2019","journal-title":". Weekly Epidemiol Rec"},{"issue":"10","key":"2024111222512048900_lgae038-B34","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/infdis\/jix476","article-title":"The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation","volume":"216","author":"Drolet","year":"2017","journal-title":"J Infect Dis"},{"issue":"10224","key":"2024111222512048900_lgae038-B35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2024111222512048900_lgae038-B36","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models","volume":"1","author":"Brisson","year":"2016","journal-title":"Lancet Public Health"},{"key":"2024111222512048900_lgae038-B37","author":"Comit\u00e9 sur l\u2019immunisation du Qu\u00e9bec (CIQ)"},{"issue":"11","key":"2024111222512048900_lgae038-B38","first-page":"300","article-title":"Use of 9-Valent Human Papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"Morb Mortal Weekly Rep"},{"key":"2024111222512048900_lgae038-B39","author":"Public Health England"},{"key":"2024111222512048900_lgae038-B40","author":"Public Health England"},{"issue":"34","key":"2024111222512048900_lgae038-B41","doi-asserted-by":"crossref","first-page":"912","DOI":"10.15585\/mmwr.mm7234a3","article-title":"Vaccination coverage among adolescents aged 13-17 years\u2014national immunization survey-teen, United States, 2022","volume":"72","author":"Pingali","year":"2023","journal-title":"Morb Mortal Weekly Rep"},{"key":"2024111222512048900_lgae038-B42","author":"Minist\u00e8re de la Sant\u00e9 et des Services Sociaux du Qu\u00e9bec (MSSS)"},{"issue":"13","key":"2024111222512048900_lgae038-B43","first-page":"1","article-title":"Human papillomavirus (HPV) vaccination coverage in adolescents in England: 2021 to 2022","volume":"16","author":"UK Health Security Agency","year":"2022","journal-title":"Health Protect Rep"},{"key":"2024111222512048900_lgae038-B44","author":"Australian Government"},{"issue":"11","key":"2024111222512048900_lgae038-B45","doi-asserted-by":"crossref","first-page":"e0206501","DOI":"10.1371\/journal.pone.0206501","article-title":"Capturing sexual contact patterns in modelling the spread of sexually transmitted infections: evidence using Natsal-3","volume":"13","author":"Datta","year":"2018","journal-title":"PLoS One"},{"key":"2024111222512048900_lgae038-B46","author":"Brisson"},{"issue":"6","key":"2024111222512048900_lgae038-B47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/OLQ.0000000000000132","article-title":"Sex in a lifetime: Sexual behaviors in the United States by lifetime number of sex partners, 2006-2010","volume":"41","author":"Haderxhanaj","year":"2014","journal-title":"Sex Transm Dis"},{"issue":"1","key":"2024111222512048900_lgae038-B48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00224499.2018.1481193","article-title":"Why do men report more opposite-sex sexual partners than women? Analysis of the gender discrepancy in a British National Probability Survey","volume":"56","author":"Mitchell","year":"2019","journal-title":"J Sex Res"},{"issue":"5","key":"2024111222512048900_lgae038-B49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/infdis\/jix333","article-title":"Modeling of US Human Papillomavirus (HPV) seroprevalence by age and sexual behavior indicates an increasing trend of HPV infection following the sexual revolution","volume":"216","author":"Ryser","year":"2017","journal-title":"J Infect Dis"},{"issue":"5","key":"2024111222512048900_lgae038-B50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jnci\/djq001","article-title":"Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2\/3: critical role of duration of infection","volume":"102","author":"Rodriguez","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2024111222512048900_lgae038-B51","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/ijc.29143","article-title":"Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection","volume":"136","author":"Gage","year":"2015","journal-title":"Int J Cancer"},{"issue":"3","key":"2024111222512048900_lgae038-B52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/infdis\/jiaa768","article-title":"Risk Factors for Non-Human Papillomavirus (HPV) type 16\/18 cervical infections and associated lesions among HPV DNA-negative women vaccinated against HPV-16\/18 in the Costa Rica vaccine trial","volume":"224","author":"Sierra","year":"2021","journal-title":"J Infect Dis"},{"issue":"2","key":"2024111222512048900_lgae038-B53","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2019.05.026","article-title":"Association of age and viral factors with high-risk HPV persistence: a retrospective follow-up study","volume":"154","author":"Li","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2024111222512048900_lgae038-B54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12916-019-1403-9","article-title":"Guidelines for multi-model comparisons of the impact of infectious disease interventions","volume":"17","author":"den Boon","year":"2019","journal-title":"BMC Medicine"},{"issue":"8","key":"2024111222512048900_lgae038-B55","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"key":"2024111222512048900_lgae038-B56","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","article-title":"Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States","volume":"339","author":"Kim","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"2024111222512048900_lgae038-B57","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2024111222512048900_lgae038-B58","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/cid\/cix475","article-title":"Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer","volume":"65","author":"Burger","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2024111222512048900_lgae038-B59","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/jnci\/djz227","article-title":"Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis","volume":"112","author":"Burger","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2024111222512048900_lgae038-B60","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/S2468-2667(20)30006-2","article-title":"Projected time to elimination of cervical cancer in the USA: a comparative modelling study","volume":"5","author":"Burger","year":"2020","journal-title":"Lancet Public Health"},{"issue":"1","key":"2024111222512048900_lgae038-B61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"issue":"1","key":"2024111222512048900_lgae038-B62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/sti.2010.044412","article-title":"Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11","volume":"87","author":"Brisson","year":"2011","journal-title":"Sex Transm Infect"},{"issue":"5","key":"2024111222512048900_lgae038-B63","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ijc.31409","article-title":"Impacts of human papillomavirus vaccination for different populations: a modeling study","volume":"143","author":"Baussano","year":"2018","journal-title":"Int J Cancer"},{"key":"2024111222512048900_lgae038-B64","author":"International Agency for Research on Cancer"},{"key":"2024111222512048900_lgae038-B65","author":"World Health Organization (WHO)"},{"issue":"3","key":"2024111222512048900_lgae038-B66","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/jnci\/djs638","article-title":"Inequalities in Human Papillomavirus (HPV)-associated cancers: implications for the success of HPV vaccination","volume":"105","author":"Brisson","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2024111222512048900_lgae038-B67","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/1055-9965.EPI-12-1173","article-title":"Sociodemographic inequalities in sexual activity and cervical cancer screening: implications for the success of human papillomavirus vaccination","volume":"22","author":"Drolet","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2024111222512048900_lgae038-B68","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.oraloncology.2009.12.004","article-title":"Socio-economic status and head and neck cancer incidence in Canada: a case-control study","volume":"46","author":"Johnson","year":"2010","journal-title":"Oral Oncol"},{"issue":"7","key":"2024111222512048900_lgae038-B69","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/IGC.0000000000000217","article-title":"Cervical cancer incidence in Ontario women: Differing sociodemographic gradients by morphologic type (adenocarcinoma versus squamous cell)","volume":"24","author":"Prummel","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"2024111222512048900_lgae038-B70","doi-asserted-by":"crossref","first-page":"E424","DOI":"10.9778\/cmajo.20200139","article-title":"Sociodemographic characteristics of women with invasive cervical cancer in British Columbia, 2004-2013: a descriptive study","volume":"9","author":"Simkin","year":"2021","journal-title":"CMAJ Open"},{"issue":"5","key":"2024111222512048900_lgae038-B71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ijc.11141","article-title":"Meta-analysis of social inequality and the risk of cervical cancer","volume":"105","author":"Parikh","year":"2003","journal-title":"Int J Cancer"},{"issue":"9","key":"2024111222512048900_lgae038-B72","doi-asserted-by":"crossref","first-page":"e2233429","DOI":"10.1001\/jamanetworkopen.2022.33429","article-title":"County-level social vulnerability and breast, cervical, and colorectal cancer screening rates in the US, 2018","volume":"5","author":"Bauer","year":"2022","journal-title":"JAMA Network Open"},{"issue":"1","key":"2024111222512048900_lgae038-B73","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/21645515.2018.1512453","article-title":"Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature","volume":"15","author":"Hirth","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"2024111222512048900_lgae038-B74","doi-asserted-by":"crossref","first-page":"e2022056597","DOI":"10.1542\/peds.2022-056597","article-title":"Human papillomavirus vaccination trends among adolescents: 2015 to 2020","volume":"150","author":"Lu","year":"2022","journal-title":"Pediatrics"},{"key":"2024111222512048900_lgae038-B75","author":"Public Health Ontario"},{"key":"2024111222512048900_lgae038-B76","author":"Institut National de Sant\u00e9 publique du Qu\u00e9bec"},{"issue":"1","key":"2024111222512048900_lgae038-B77","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1055-9965.EPI-14-1052","article-title":"Changing inequalities in cervical cancer: modeling the impact of vaccine uptake, vaccine herd effects, and cervical cancer screening in the post-vaccination era","volume":"24","author":"Malag\u00f3n","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2024111222512048900_lgae038-B78","volume-title":"Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Female School Students in Thailand","author":"Jiamsiri","year":"2024"},{"key":"2024111222512048900_lgae038-B79","author":"Burger"},{"issue":"9548","key":"2024111222512048900_lgae038-B80","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(06)69479-8","article-title":"Sexual behaviour in context: a global perspective","volume":"368","author":"Wellings","year":"2006","journal-title":"Lancet"},{"issue":"10","key":"2024111222512048900_lgae038-B81","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"issue":"2","key":"2024111222512048900_lgae038-B82","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Global Health"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2024\/67\/387\/60629497\/lgae038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2024\/67\/387\/60629497\/lgae038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T22:51:51Z","timestamp":1731451911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2024\/67\/387\/7821495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":82,"journal-issue":{"issue":"67","published-online":{"date-parts":[[2024,11,12]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgae038","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10]]}}}